Search Results
Your search for ,New matches 16916 pages
Showing 14001 - 14050Hookah Tobacco Smoking Among Students
Educational campaigns meant to dissuade college students from initiating hookah tobacco smoking may be more successful if they combat positive perceptions of hookah use as attractive and romantic, rather than focusing solely on the harmful components of hookah tobacco smoke, a new University of...
Helping Young Adults Cope With Cancer
For young adults diagnosed with cancer, coping with the aftermath of the disease can be especially daunting. Although all cancer survivors share some common concerns and distress, for young adults grappling with body image, sexuality, peer pressure, dating, marriage, family planning, education, and ...
Should Breast Cancer Patients With One to Three Positive Nodes Routinely Receive Postmastectomy Radiation?
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) continues to provide valuable clinically relevant and practice-influencing information garnered from individual patient-level data from numerous randomized trials in breast cancer. The large numbers of patients and long-term follow-up...
ASCO Guideline Update Extends Sentinel Node Biopsy Indications in Breast Cancer
The American Society of Clinical Oncology (ASCO) published its first guideline for sentinel lymph node biopsy in 2005.1 Since that time, many new randomized and cohort studies have been published investigating the indications and outcomes of the procedure. The updated 2014 guideline, recently...
ASCO Clinical Practice Guideline Update: Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer
ASCO recently convened an update committee of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline implementation, and advocacy to develop evidence-based recommendations that update the ASCO 2005 clinical practice guideline on use of sentinel node biopsy in...
Unprecedented Release of Medicare Data Raises Concerns About Lack of Context: Statements From COA and ASTRO
In April, as part of the Obama administration’s work to make the U.S. health-care system more transparent, affordable, and accountable, the Centers for Medicare & Medicaid Services (CMS) released a vast amount of privacy-protected data on services and procedures provided to Medicare...
Patients Benefit From Faster FDA Drug Approval Process
In an increasing spirit of cooperation, U.S. Food and Drug Administration (FDA) and several pharmaceutical companies are bringing to fruition the newest in a series of ways to expedite drug development and review. Breakthrough therapy is the designation instituted in 2012 by the FDA Safety and...
Looking Ahead in Treating Chronic Lymphocytic Leukemia
It’s the dawn of a new era in the treatment of chronic lymphocytic leukemia (CLL), largely due to the development of agents targeting the BCR signaling pathway, according to John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, Columbus. At the 19th Annual Conference of the...
NCCN Scientific Posters Include New Findings in Bladder Cancer, Survivorship Care, and Antiemetic Therapy
The 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), recently held in Hollywood, Florida, featured a number of scientific posters by member organizations and meeting sponsors. The ASCO Post captured some of the most interesting findings for our readers, including these...
Study Calls for Revisiting Guidelines for Screening Childhood Cancer Survivors at Risk of Congestive Heart Failure
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure found improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit. The...
Surveillance After Colon Cancer Surgery: Too Much of a Good Thing?
Finding salvageable colon cancer recurrence is akin to finding a needle in a haystack, rendering routine patient surveillance of little value. But finding that needle offers an opportunity for treating recurrent disease early, which makes surveillance worthwhile. These were the opposing views...
AACR Calls on Congress to Support Cancer Research Funding to Meet the Challenges of Our Aging Population
Great progress is being made in the battle against cancer, but a renewed commitment of federal support for medical research is needed to speed its eradication, according to leaders of the American Association for Cancer Research (AACR), commenting in connection with a recent Senate hearing on “The...
Glioblastoma: Can We Make This Intractable Disease Tractable?
In the clinical array of brain tumors, glioblastoma is the most difficult to treat, and despite decades of research and the advent of new therapies, patients with glioblastoma continue to have a very poor prognosis. Leading brain tumor experts at the recent 25th Annual Cancer Progress Conference in ...
Cryoablation of Breast Tumors Shows Promise in Patients With Early-Stage Disease
Cryoablation of breast tumors, which destroys lesions by exposing them to extremely low temperatures, shows promise as an alternative to surgery in carefully selected women with early-stage disease, according to a study presented at the American Society of Breast Surgeons Annual Meeting in Las...
Expert Point of View: Clifford A. Hudis, MD, FACP
“To our surprise, obesity had a negative prognostic effect on premenopausal patients with breast cancer but not on those who were postmenopausal. We need to consider these findings in the context of results from other data sources that suggest that obesity remains a negative prognostic feature in...
Delaying Androgen Deprivation Therapy May Not Compromise Survival in Men With Prostate Cancer and PSA-Only Relapse
In men with prostate cancer and a prostate-specific antigen (PSA)-only recurrence after curative surgery or radiation, delaying androgen deprivation therapy for at least 2 years or until clinical progression (ie, new symptoms, metastasis by imaging techniques or short PSA doubling time) did not...
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Preliminary evidence suggests that AZD9291, a novel mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, may become a treatment option for patients with advanced, EGFR-mutant, non–small cell lung cancer (NSCLC) that has progressed on standard EGFR inhibitors....
Expert Point of View: George W. Sledge, Jr, MD
In his commentary on the ALTTO results, George W. Sledge, Jr, MD, Professor of Medicine and Director of the Division of Oncology at Stanford University, reminded attendees that the announcement of the first results for adjuvant trastuzumab, which occurred at the 2005 ASCO Annual Meeting, was “a...
SIDEBAR: MEDCAC Roster
Rita Redberg, MD, MS, Chair Professor of Medicine UCSF School of Medicine Division of Cardiology University of California, San Francisco, Medical Center Art Sedrakyan, MD, PhD, Vice ChairAssociate Professor and DirectorPatient Centered Comparative Outcomes Research ProgramWeill Cornell Medical...
Medicare Advisory Panel Cast Doubts on Lung Cancer Screening, Leaving Advocates Dismayed but Undaunted
On April 30, 2014, the Centers for Medicare & Medicaid Services (CMS) convened the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to assess the value of low-dose computed tomography (CT) lung cancer screening in the Medicare population. After a decades-long battle,...
'Small Practices Like Mine'
Recently, I participated in ASCO’s Congressional news briefing in Washington, DC, following the release of its report, The State of Cancer Care in America: 2014. During my presentation I talked about the workforce shortage of approximately 1,500 medical oncologists that is predicted by 2025. A...
Expert Point of View: Michael J. Morris, MD
Formal discussant of the E3805 study, Michael J. Morris, MD, Associate Member at Memorial Sloan Kettering Cancer Center in New York, said that these results confirm the role of upfront chemotherapy along with androgen-deprivation therapy in men with newly diagnosed metastatic hormone-sensitive...
‘Unprecedented’ Survival Benefit in Prostate Cancer With Addition of Docetaxel to Hormone Therapy
Adding docetaxel to standard androgen ablation therapy (ie, testosterone suppression) extended survival by more than 1 year in men with newly diagnosed metastatic hormone-sensitive prostate cancer in the phase III E3805 trial, funded by the National Institutes of Health. As reported at the ASCO...
Sharing 50 Years of Christmas: A Quality Metric?
A very pleasant 68-year-old woman was referred to my clinic with biopsy-proven liver metastasis from primary colon cancer. She was initially diagnosed with colon cancer, which was resected, and she then received chemotherapy. A suspicious liver lesion was biopsied in the adjuvant setting, which...
Leading Cancer Researcher and Public Health-Care Expert, Eddie Reed, MD, Dies
In a 2010 interview, Eddie Reed, MD, a pioneer in the molecular pharmacology of DNA-damaging anticancer agents and the clinical development of paclitaxel for ovarian cancer, was asked what lay ahead. Before answering, Dr. Reed first acknowledged the esteemed mentors who gave him their most precious ...
Colorectal Cancer Screening Recommended Past Age 75 for Previously Unscreened Patients
Colorectal cancer screening is cost-effective and “should be considered well beyond age 75 years” for individuals not previously screened, according to a computer simulation study published in the Annals of Internal Medicine. The researchers noted that while the U.S. Preventive Services Task Force...
Focus on the Washington State Medical Oncology Society
The Washington State Medical Oncology Society (WSMOS) was formed in 1993 in response to the health-care reform legislation then being proposed by President Bill Clinton. “The law never passed, but it spurred the development of our Society, so some good came out of the law’s defeat,” said Vicky E....
Expect Questions From Patients
With the extensive media coverage of a study indicating that injections with the luteinizing hormone–releasing hormone (LHRH) agonist goserelin (Zoladex) may offer a new option for preserving fertility among women treated for breast cancer, physicians can expect questions from interested patients....
New Option for Preserving Fertility in Women Being Treated With Chemotherapy for Early-Stage Breast Cancer
One of the most reported studies emanating from the 2014 ASCO Annual Meeting involves the use of the luteinizing hormone–releasing hormone (LHRH) agonist goserelin (Zoladex) to reduce the risk of ovarian failure among women being treated with chemotherapy for early-stage breast cancer, and to...
2014 Oncology Meetings
JUNE MASCC/ISOO International Symposium on Supportive Care in CancerJune 26-28 • Miami, Florida For more information: www.mascc.org/symposium European Conference of Oncology Pharmacy 2June 26-28 • Krakow, Poland For more information: http://ecop2014.wordpress.com 6th International Workshop on...
Genomic Confidence and Competence
As reported in the Journal of Clinical Oncology and reviewed in this issue of The ASCO Post, Stacy W. Gray, MD, AM, a medical oncologist at Dana-Farber Cancer Institute, Boston, and colleagues presented one of the first studies evaluating how academic oncologists perceive the incorporation of a...
Physician Attitudes About Multiplex Tumor Genomic Testing: Variation in Projected Use and Confidence
It is a widely expressed belief that predictive multiplex somatic genomic testing represents the ability to transform cancer care by identifying targetable alterations in multiple cancer genes. Do oncologists share this belief? How do they intend to use such tests in practice? In a study reported...
Cancer Care Under the Affordable Care Act
The problematic rollout of the Affordable Care Act’s website, HealthCare.gov, made good political theater, but while much of the heated discussion centered on the plan’s need to enroll “young invincibles,” America’s cancer care system and the older patients it serves were also affected by parts of...
Marie-Josée and Henry R. Kravis Foundation Provides $100 Million Gift to Support Precision Oncology Work at Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center has launched an initiative to improve cancer care and research through genomic analysis. The new program will reshape clinical trials and speed the translation of novel molecular discoveries into routine clinical practice. The Marie-Josée and Henry R. Kravis...
Maurie Markman, MD, Named President of Medicine & Science Unit, Cancer Treatment Centers of America
Cancer Treatment Centers of America (CTCA) recently announced the appointment of Maurie Markman, MD, as President of the company’s Medicine & Science unit. He will be responsible for advancing the organization’s overall commitment to clinical excellence, innovation, safety, and patient...
Colon Cancer Prevention: It’s All About Mindset and Minute Details
I would like to congratulate Corley and his colleagues for their seminal work on the association between adenoma detection rate and risk of colorectal cancer, advanced colorectal cancer, and colorectal cancer mortality. The impact of their findings—reported in The New England Journal of Medicine1...
Colonoscopy Adenoma Detection Rate Inversely Proportional to Risk of Interval Colorectal Cancer and Colorectal Cancer Mortality
In a study of health-care organization data reported in The New England Journal of Medicine, Douglas A. Corley, MD, PhD, of Kaiser Permanente, and colleagues assessed the relationship between proportion of colonoscopies performed by a gastroenterologist that detect an adenoma and risk of subsequent ...
Paying It Forward: Breakthrough Prize Winners and Institutions Commit $3 Million in Support of Next Generation of Scientists
Following last year’s announcement of the first-ever Breakthrough Prizes, established by a group of Silicon Valley entrepreneurs to celebrate scientists and encourage careers in the field, the winners were frequently asked what they would do with their newfound prize money of $3 million each. Three ...
Issues in the Management of the Axilla in Patients With Breast Cancer
For the past 40 years the story of breast cancer surgery in general, and for the past 20 years the management of the axilla in particular, has been one of increasing conservatism. To give our readers insight into the current and future direction of axillary management, The ASCO Post spoke with...
A New Era in the Management of Advanced HER2-Positive Breast Cancer
Approximately 20% of all breast cancers are human epidermal growth factor receptor 2 (HER2)-positive. Prior to the era of HER2-targeted therapy, HER2-positive breast cancer was characterized by a poor prognosis.1,2 The development of the first HER2-targeted therapy, trastuzumab (Herceptin), led to...
ASCO Clinical Practice Guideline: Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
Approximately 15% of patients with breast cancer have tumors that overexpress the HER2 protein and these patients can benefit from HER2-targeted therapies. The American Society of Clinical Oncology recently released a clinical practice guideline on systemic therapy for patients with advanced...
Videos Tell Stories of 50 Years of Progress Against Cancer
Nearly 3 years ago, ASCO launched CancerProgress.Net to mark the 40th anniversary of the signing of the U.S. National Cancer Act, which led to major new investments in cancer research and significant increases in cancer survival. The site provides a dynamic and interactive history of progress...
ASCO’s Patient Information Website, Cancer.Net, Undergoes Redesign
ASCO is committed to providing people with cancer and their caregivers with top quality educational information and resources to help them manage their cancer care, treatment, and survivorship. This ongoing commitment is best reflected in its patient-facing educational website, Cancer.Net...
Help Your Patients Catch Up on the Latest Research From the 2014 ASCO Annual Meeting
Direct your patients to www.cancer.net/blog for podcasts with ASCO experts discussing the research that was presented at the 2014 ASCO Annual Meeting. This series of “Research Round Up” podcasts provides the latest information on treatment and care for people with cancer and will help your patients ...
Conquering Cancer With 2013 Career Development Award Recipient Rebecca A. Gardner, MD
Rebecca A. Gardner, MD is an Assistant Professor at the University of Washington and Attending Physician at Seattle Children’s Hospital. She received a 2013 Conquer Cancer Foundation of ASCO Career Development Award (CDA) for her project “Autologous T cells genetically modified to express a CD19...
FDA Approves Radioactive Diagnostic Imaging Agent to Help Determine the Extent of Head and Neck Cancer in the Body
The U.S. Food and Drug Administration has approved a new use for technetium 99m tilmanocept (Lymphoseek Injection), a radioactive diagnostic imaging agent used to help doctors determine the extent to which squamous cell carcinoma has spread in the body’s head and neck region. In 2013, tilmanocept...
Colorectal Cancer Screening Poised for Change
New screening modalities and the customization of the screening population could soon change the way that screening for colorectal cancer is done. At Digestive Disease Week 2014, the largest gathering of gastrointestinal disease specialists in the world, researchers presented data suggesting that...
Preoperative Breast MRI: Does Higher Sensitivity Equal Better Outcomes?
Breast magnetic resonance imaging (MRI) is superior to more commonly used imaging modalities in preoperative breast cancer staging and should be a key element in routine workup. But despite its high sensitivity for catching cancers, breast MRI still does not deliver maximum value for the patient....
Lung-MAP Launches: First Precision Medicine Trial From National Clinical Trials Network
A public-private collaboration among the National Cancer Institute (NCI), SWOG Cancer Research, Friends of Cancer Research, the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D...
Research Insights From the AACR Special Conference on Pancreatic Cancer
Pancreatic cancer still kills 40,000 Americans a year out of approximately 44,000 diagnosed. While advances in diagnosis and treatment are extending the lives of patients with other cancers, pancreatic ductal adenocarcinoma remains the second most lethal tumor (behind lung cancer). While a magic...
